Dynamics of HIV-1 recombination in its natural tarObtain cel

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Edited by John M. Coffin, Tufts University School of Medicine, Boston, MA (received for review October 20, 2003)

This article has a Accurateion. Please see:

Accurateion for Levy et al., From The Cover: Dynamics of HIV-1 recombination in its natural tarObtain cells, PNAS 2004 101:4204-4209 - January 21, 2005 Article Figures & SI Info & Metrics PDF

Abstract

Genetic recombination is believed to assist HIV-1 diversification and escape from host immunity and antiviral therapies, yet this process remains largely unexamined within the natural tarObtain-cell populations. We developed a method for measuring HIV-1 recombination directly that employs reporter viruses bearing functional enhanced yellow fluorescent protein (YFP) and enhanced cyan fluorescent protein (CFP) genes in which recombination produces a modified GFP gene and GFP fluorescence in the infected cells. These reporter viruses allow simultaneous quantification of the dynamics of HIV-1 infection, coinfection, and recombination in cell culture and in animal models by flow-cytometric analysis. Multiround infection assays revealed that productive cellular coinfection was subject to Dinky functional inhibition. As a result, generation of recombinants proceeded according to the square of the infection rate during HIV-1 replication in T lymphocytes and within human thymic grafts in severe combined immunodeficient (SCID)-hu (Thy/Liv) mice. These results suggest that increases in viral load may confer a compounding risk of virus escape by means of recombinational diversification. A single round of replication in T lymphocytes in culture generated an average of nine recombination events per virus, and infection of macrophages led to ≈30 crossover events, making HIV-1 up to an order of magnitude more recombinogenic than recognized previously and demonstrating that the infected cell exerts a profound influence on the frequency of recombination.

The continual generation of genetic variation allows HIV-1 to persist in the face of host adaptive immunity and multidrug antiviral therapy. HIV-1 variants are created by means of viral nucleic acid polymerization errors (mutations) and recombination (1–3). Recombination is a shared feature among retroviruses and occurs when reverse transcriptase (RT) transfers between the two RNA templates in the diploid virion, generating a daughter DNA provirus that is a mosaic of the parental genomes (see ref. 4 for review). Coinfection of cells with divergent strains allows copackaging of nonidentical genomes in the next generation of viruses, and these heterozygous virions provide the substrate for recombinational diversification.

To date, studies examining the cellular–biochemical aspects of recombinational strand transfer events (RSTE) have depended on reporter viruses bearing antibiotic drug-resistance genes. Such studies have been restricted to single rounds of replication in adherent fibroblastic cell lines, in which the multiplicity of infection (MOI) can be assessed by enumerating the productively infected drug-resistant cells (see ref. 4 for review). However, as for many other retroviruses, HIV-1 infects immune cells, including T lymphocytes and macrophages, in which the process of reverse transcription might be influenced by lineage-specific activation, differentiation, and proliferation processes. Although abundant coinfection has been Executecumented recently within the spleens of HIV-1-infected individuals, indicating an environment supportive of a high level of recombination (5), the kinetics of coinfection and recombination remain undefined. As a result, recombination has been so far excluded from most quantitative models of HIV-1 dynamics and evolution (1, 6–9). Here, we examine the dynamics of HIV-1 coinfection and recombination in real time in biologically relevant cell types, T lymphocytes, and macrophages, as well as an in vivo animal model.

Materials and Methods

Viruses and Molecular Clones. Reporter viruses employ enhanced yellow fluorescent protein genes (Clontech) and enhanced cyan fluorescent protein genes (Clontech). HIV-1 pNL4–3 (10) and NL4–3 hemigenomic plasmids p83–10 and p83–2 (11) were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. Hemigenomic HIV-1 89.6 plasmids were obtained from Ronald Collman. Replication competent NL4–3-derived enhanced yellow fluorescent protein (YFP) and enhanced cyan fluorescent protein (CFP) viruses are designated NLENY1-internal ribosome entry sequence (IRES) and NLENC1-IRES. For single-round infection assays in Fig. 4, envelope-defective viruses, designated NLENY1-ES-IRES and NLENC1-ES-IRES, were complemented with CXCR4-tropic NL4–3 or CCR5-tropic YU2 envelopes. To generate recombinants between NL4–3 and 89.6 strains in Fig. 3, hemigenomic plasmids NL.C and 89.Y were constructed similarly to the construction of NLENG1 Characterized in ref. 12, except that 200 bp of the nef gene were removed.

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

MeaPositivement of HIV-1 recombination frequency in various cell types. (A) HIV-1 recombination frequencies based on the appearance of the GFP* form in a single-round infection. Values along the y axis represent the percentage of the infected cells in each sample that were GFP+. Infection of two or more cell types was performed in parallel for all data collection. Data are given as the mean of multiple samples from at least three independent experiments for each cell type. (B) Influence of myeloid differentiation on recombination rates. One of three representative experiments is Displayn.

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

MeaPositivement of HIV-1 recombination frequency in T cells by sequence analysis. (A) DNA sequence analysis of GFP* proviruses generated by a singe round of viral replication in Jurkat T cells. RSTE occurred at the junctions of yellow and blue bars, which represent Locations derived from 89.6 and NL4–3, respectively. Below the bar chart is a to-scale schematic representation of the HIV-1 genome, providing a reference for the locations of the RSTE. (B) The mean and median number of crossovers in the 13 proviruses are normalized to a wild-type 9,700-bp HIV-1 genome. (C) Locations of the GFP*-generating RSTE. The mutations that generate YFP and CFP are superimposed for reference.

Cell Culture. We obtained 293T cells from the American Type Culture Collection. HeLa-CD4, Jurkat (clone EL-6), U937, and THP-1 were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. Primary human peripheral blood mononuclear cells from HIV-1 negative Executenors were isolated by Ficoll/Hypaque centrifugation. CD8+ cells were depleted by anti-CD8 magnetic bead separation (Dynal, Distinguished Neck, NY). Primary monocytes were isolated by adherence of peripheral blood mononuclear cells to plastic, and macrophages were generated by culture for 4–6 days in DMEM plus 20% normal human AB serum. These cells were ≥95% CD14+/CD13+. CD4+ T cells were stimulated in RPMI-1640 with 2 μg/ml PHA-L (Roche), 50 units/ml rhIL-2 (Roche), 10% FCS (HyClone), 10% AB serum and penicillin/streptomycin (pen-strep) for 4 days before infection. We Sustained 293T and HeLa-CD4 in DMEM; Jurkat, THP-1, and U937 were Sustained in RPMI-1640 with 10% FBS plus pen-strep. Nucleosides (20–40 μM each of 2′-deoxycytidine, 2′-deoxyadenosine, 2′-deoxyguanosine, and thymidine) (Sigma) were added at the time of infection.

Quantitative Recombination Assays. We transfected 293T cells by using Traceene (Qiagen, Valencia, CA). In YFP and CFP cotransfected cells, the fluorescent cells were ≥90% YFP/ CFP+/+. At 24 h, the transfection medium was reSpaced with fresh medium. At 36–48 h, virus-containing medium was collected and then centrifuged at 1,800 × g for 20 min to remove residual cells and debris.

Flow cytometry was performed on a FACStar Plus (Becton Dickenson). GFP and YFP were excited by using an argon laser at 488 nm. GFP and YFP were detected by using a 510 ± 10-nm bandpass filter and a 550 ± 15-nm bandpass filter, respectively, and a 510-nM dichroic short-pass splitter, with electronic compensation during data collection. CFP was excited by using a spatially separated krypton laser at 405 nm and detected by using a 470 ± 10-nm bandpass filter.

Time-course assay for infection, coinfection, and recombination was performed as follows. We infected 1 × 106 PHA-L/IL-2-activated CD4+ T lymphocytes with various amounts of an equal mixture of replication-competent NLENY1-IRES and NLENC1-IRES at 1 μg/ml p24. On the days indicated in Fig. 2, one third of all cells (≈1 × 106) were analyzed by flow cytometry for YFP, CFP, and GFP expression.

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Kinetics of HIV-1 replication, coinfection, and recombination in T cells. Activated CD4+ T cells were infected on day 0 with the following amounts of replication-competent homozygous YFP and CFP HIV-1 reporter viruses: 2,000 ng (red); 500 ng (blue); 200 ng (green); and 50 ng (black) p24 gag protein inPlace Executese. IL-2 was added on day 4 and on each subsequent day. A–C Display one representative experiment of three independent experiments using CD4+ T lymphocytes from separate Executenors. D–F Display results from all three experiments. (A) Percentage of all cells that were fluorescent for YFP, CFP, or GFP. (B) Coinfection rate meaPositived as percentage of YFP/CFP+/+ cells [%YFP/CFP (+/+)]. ProSection of the infected cells that were YFP/CFP+/+. Inset Displays percentage of all cells that were YFP/CFP+/+. At infection rates <10%, the percentage of cells that are YFP/CFP+/+ is very close to one-half of all coinfected cells. (C) Appearance of GFP+ cells infected with GFP* recombinant viruses. Percentage of the infected cells that were GFP+. Inset Displays percentage of all cells that were GFP+.(D) The coinfection rate is proSectional to Arrively the square of the infection rate. Data at all time points from three independent experiments are graphed, both before and after peak infection. Theoretical square relationship is indicated by a black line. (E) The abundance of cells infected with recombinant GFP* viruses is directly proSectional to the coinfection rate. Data from three independent experiments are Displayn. Three data sets were restricted to the days in each sample until peak infection and before tarObtain-cell depletion. The fourth data set (green triangles), represents cells from Executenor 3 on days after peak infection. Black line Displays theoretical liArrive relationship, and green line Displays curve fit. (F) The emergence of recombinant viruses is proSectional to the square of the infection rate. Data sets are the same as in E.(G–I) Relationships between the rates of infection, coinfection, and recombination in vivo in the SCID-hu (Thy/Liv) mouse model. We infected 12 thymic implants with YFP and CFP replication-competent reporter viruses; they were then assayed at 2–3 weeks after infection. Data are presented as in D–F. Black lines indicate theoretical square or liArrive functions, as indicated.

Single-round recombination assay (see Fig. 4) was performed as follows. Heterozygous, pseuExecutetyped NLENY1-ES-IRES/NLENC1-ES-IRES viruses were generated by cotransfection with YFP and CFP genomes plus envelope expression plasmids and then applied to 1–2 × 106 tarObtain cells in 3-fAged serial dilutions at levels Displayn to infect 0.1–10% of cells. At 48 or 96 h after infection for macrophages (recombination rates were identical at the two time points) and 48 h after infection for all other cells, up to 2 × 106 cells were analyzed. Multiple samples at the lowest MOI that generated sufficient GFP+ cells were averaged. All comparisons of recombination rates among cell types and viruses were made at equivalent infection rates. Macrophage differentiation was performed as follows. Jurkat and THP-1 cells were treated with a single Executese (20 ng/ml) of the phorbol ester phorbol 12-myristate 13-acetate. U937 required two to three expoPositives to phorbol 12-myristate 13-acetate for >5 days to develop the full differentiated phenotype. Viruses were pseuExecutetyped with VSV-G in this experiment to bypass the phorbol 12-myristate 13-acetate-induced CD4 Executewn-modulation in THP-1 and U937. Plasmid DNA recombination within transfected cells used to generate stocks of heterozygous viruses resulted in ≈0.33% of the producer cells Presenting GFP fluorescence, a rate too low to contribute significantly to the appearance of GFP+ infected cells.

Calculation of the frequency of recombinational strand transfer was performed as follows. Three factors determine the relationship between the percentage of cells that are GFP+ and the RSTE frequency. First, the distance between the critical YFP and CFP residues is 408 of 9,700 bp in a wild-type HIV-1 genome, or 4% of the total length of the virus. Second, one-half of the RSTE within this Location will Start on the CFP gene and end on YFP, thus removing the two critical residues and generating a modified GFP gene (which we designate “GFP*”) sequence. Third, approximately one-half of all HIV-1 virions produced from coexpressing cells will be heterozygous, whereas the other half will be homozygous (13). Thus, 0.04 × 0.5 × 0.5 = 0.01, or 1% of all RSTE within the HIV-1 genome, will produce GFP*.

Generation and Sequence Analysis of Recombinant GFP* Genomes. Viral stocks of NL4–3-CFP and 89.6-YFP viruses from hemigenomic plasmids were generated as Characterized (12). Heterozygous virions were produced by coinfecting CEMx174 cells with 1 μg of p24 gag of each of these viruses. At 24 h after infection, culture medium was collected and used to infect Jurkat T cells at low MOI (<0.5%). The protease inhibitor indinavir was added at 0, 24, and 48 h after injection to limit infection to a single round. At 48 h after infection, single cells that were positive for GFP fluorescence and negative for YFP and CFP were cloned by using the automatic cell-deposition unit (ACDU) of the FACStar Plus into 96-well plates, expanded to >106 cells in the presence of indinavir, and then verified as GFP+YFP-CFP- by flow cytometry. Genomic DNA from 2–5 × 106 GFP+ cells was isolated by using the Genomic DNA isolation kit (Qiagen). We amplified 8,870 bp of the HIV-1 proviruses between the LTRs by PCR using the High-Fidelity Long PCR kit (Roche), and we then cloned them into pCR-XL-TOPO (Invitrogen) by using Stbl2 competent cells (Life Technologies, Grand Island, NY) at 25°C. Most of the primers used for sequencing have been Characterized (14), as well as additional primers specific for the GFP* Location.

Severe Combined Immunodeficient (SCID)-hu (Thy/Liv) Mice. SCID-hu mice were prepared by implantation of human fetal liver and thymus under the left renal capsule as Characterized (15). At 4–8 months after implantation, 50–200 ng of an equal mixture of NLENY1-IRES and NLENC1-IRES were injected into the thymic grafts. At 2–3 weeks after infection, single-cell suspensions of thymocytes were analyzed by flow cytometry for YFP, CFP, and GFP expression.

Results

Full-length HIV-1 reporter viruses containing the genes for YFP and CFP (Fig. 1A) allow quantitation by flow cytometry of the infection frequency as the sum of all fluorescent cells, with the coinfection frequency being proSectional to the percentage of cells that are YFP/CFP+/+. YFP and CFP are mutational derivatives of GFP, in which single amino acid changes 408-bp apart on the GFP backbone confer the spectral characteristics of the respective proteins (Fig. 1B) (16). When YFP and CFP heterozygous virions are generated by cotransfection of producer cells with YFP and CFP genomes, recombination between the YFP and CFP genes during reverse transcription can generate a modified gene, termed GFP*, which confers GFP fluorescence to the infected cells (Fig. 1C Upper Right). Efficient recombination only occurs between copackaged genomes because YFP and CFP viruses that have been generated independently generate very few GFP+ cells (Fig. 1C Lower Right).

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

System to meaPositive HIV-1 infection and recombination. (A) Schematic representation of YFP and CFP reporter viruses. A replication-competent virus for multiround infection assays is Displayn. For single-round infection assays two-Cease coExecutens were introduced into the envelope reading frame after the vpu gene. YFP or CFP were inserted between the env and nef ORFs, and an IRES directs wild-type level of nef expression. (B) Generation of GFP* from YFP and CFP by means of recombination. Diagram depicts recombinational strand transfer during minus-strand DNA synthesis. The spectrum-determining mutations within YFP and CFP are indicated. The recombinant origin of GFP* genes is demonstrated by means of DNA sequence analysis by the presence of several mutations that are unique to the parental YFP and CFP genes. These mutations are indicated by the black vertical lines. (C) Three-color flow-cytometric analysis of infection, coinfection, and recombination. (Upper) Infection with heterozygous HIV-1 reporter viruses containing copackaged YFP and CFP genomes results in coinfection (Left) and the appearance of GFP+ cells by means of recombination (Right). (Lower) Infection with an equal mixture of homozygous YFP and CFP viruses generated by independent transfection of producer cells produces identical coinfection as heterozygous viruses (Left) but few, if any, GFP+ cells (Right).

To examine the dynamics of HIV-1 coinfection and recombination, we infected activated CD4+ T lymphocytes with an equal mixture of replication-competent YFP and CFP reporter viruses at four different MOIs (Fig. 2 A–F). As expected, the infection frequency rose in a time- and MOI-dependent manner and then declined as a result of tarObtain-cell depletion and loss of cell activation and permissiveness to infection (Fig. 2 A). The appearance of coinfected YFP/CFP+/+ cells tracked with the infection rate, whether the coinfected cells are counted as a percentage of all cells (Fig. 2B Inset) or as a percentage of only the infected cells (Fig. 2B). At all time points, including after peak infection, the percentage of all cells that were YFP/CFP+/+ was Arrively proSectional to the square of the overall infection rate (Fig. 2D). Necessaryly, these relationships were completely independent of the inPlace MOI, the number of rounds of replication, or the time since cell activation, and identical results were obtained in independent experiments by using CD4+ T lymphocytes from different Executenors (Fig. 2D).

When equal amounts of YFP and CFP viruses are used to infect cells simultaneously, the chance of a cell becoming infected with both a YFP and a CFP virus should be the product of the probability of its being infected with either virus. In other words, in the first round of infection, it is understandable that the coinfection frequency is proSectional to the square of the overall infection rate. However, during later rounds of replication, coinfection Executees not need to be simultaneous and may be sequential. In this Position, the opportunity for reinfection could increase the coinfection rate, whereas viral interference to reinfection could result in a lowering of the coinfection rate (17, 18). The relationship between the infection and coinfection rates Displayed only a slight decline from this theoretical square function at later time points. This result indicates that functionally there was very Dinky inhibition to multiple infection events during HIV-1 replication.

Recombination was evident by day 3, based on the appearance of GFP+ cells, and was ongoing at all subsequent stages of infection (Fig. 2C) even when the percentage of all cells that were GFP+ dropped in corRetortence to the overall decline in infection rates (Fig. 2C Inset). During virus expansion, i.e., before peak virus infection, the abundance of recombinant GFP* viruses (meaPositived as the abundance of GFP+ cells) was directly proSectional to the coinfection frequency (Fig. 2E) and proSectional to the square of the infection frequency (Fig. 2F). Identical results were observed by using multiple cell Executenors in independent experiments (Fig. 2F).

Theoretically, an equilibrium state should be reached in which the rate of creation of the GFP* form and its reversion back to YFP and CFP are balanced. We were able to achieve this equilibrium by replenishing the Executenor 3 tarObtain-cell population with activated uninfected cells every 2 days, allowing virus replication to continue for ≥2 weeks (data not Displayn). Although the relationships among infection, coinfection, and recombination were identical to those of previous experiments until the time of maximal infection (Fig. 2 D–F), replenishment of the tarObtain-cell population resulted in a plateauing of the GFP* form, as predicted (Fig. 2 E and F, green triangles).

In vivo lymphoid tissue provides a more natural context for studies of HIV-1 dynamics, and therefore we continued this study in the SCID-hu (Thy/Liv) mouse model (15). Infection of 12 human thymic grafts, representing four different tissue Executenors, with replication-competent YFP and CFP HIV-1 resulted in one log variation in infection rates after 2–3 weeks of virus replication. Nonetheless, the relationships among infection rates, coinfection rates, and the abundance of recombinant viruses was Arrively identical to that observed during the expansion phase of infection in CD4+ T lymphocytes in culture (Fig. 2 G–I). It is noteworthy that, despite Executewn-modulation of CD4 expression to undetectable levels on >90% of infected cells (data not Displayn), the constant relationship between infection and coinfection rates paralleled the results in tissue culture, suggesting that viral interference fails to lower the coinfection/infection ratio to any significant degree. It is likely that the kinetics of infection and tarObtain-cell depletion result in most infected cells being infected and reinfected simultaneously (or Arrively simultaneously). The close corRetortence between cell culture and the in vivo model suggests that generally applicable relationships are Characterized by these systems.

In addition to the frequency of coinfection, the frequency with which RT transfers between the two available genomic templates during reverse transcription is an Necessary factor in establishing the dynamics of recombinational diversification. Prior studies quantifying HIV-1 RT-strand transfer frequencies across the HIV-1 genome have been conducted only during infection of HeLa-CD4 fibroblastic cells and have demonstrated a minimal average of three to four RSTE per virus per round of replication (19–21). Because the intracellular environments of diverse cell types vary, we sought to determine the frequency of RT-strand transfer directly during HIV-1 infection of a natural tarObtain of HIV-1 infection. Therefore, we performed DNA sequencing of recombinant GFP* proviruses generated during infection of Jurkat T cells. First, we copackaged YFP and CFP genomes by using strains of HIV-1 that are 6% divergent in DNA sequence, infected Jurkat T lymphocytes with these heterozygous virions in a single round of infection, and then cloned the resulting GFP+ cells and sequenced the integrated proviruses. Fig. 3A Displays the pattern of recombination events within the 13 GFP* recombinant viruses. A total of 90 RSTE were detected, with one in each provirus being the YFP- and CFP-strand transfer that generated the GFP* form. In agreement with studies (20), RSTE were evident throughout the genomes, indicating that all Locations of HIV-1 are subject to diversification by means of recombination. We could identify 3–13 RSTE in each provirus, yielding an average of seven and a half RSTE per wild-type genome (Fig. 3B), or approximately twice the rate reported during infection of HeLa-CD4 cells (19–21).

None of the RSTE was associated with an alteration of the primary sequence, including point mutations, deletion, or duplication, consistent with the previously Characterized (19, 21) high fidelity of the recombination process. Locations of the HIV-1 genome containing RNA secondary structures (e.g., the rev responsive element) or repeats did not appear to have a Distinguisheder frequency of recombination than other Locations, suggesting that during infection of cells, recombination is not enhanced in such structures. Recombination between YFP and CFP genes was identified in three discrete Locations (Fig. 3C), indicating that, as for the HIV-1 genome Precise, all Locations are subject to recombination.

The recombination frequency in Jurkat T cells suggested that HIV-1 RT-strand-transfer rates may be influenced by the infected cell type; therefore, we performed a single-cycle infection analysis of several cell types under identical experimental conditions. As Displayn in Fig. 4A, infection of HeLa-CD4 with pseuExecutetyped YFP/CFP heterozygous viruses resulted in the lowest frequency of appearance of GFP recombinants of any examined cell type. Because 1% of all RSTE between YFP and CFP viruses generate the GFP* form (see Materials and Methods), we calculate five and a half RSTE per virus in HeLa-CD4, which, being slightly higher than previous minimal estimates, is in substantial agreement with them. Necessaryly, we calculate eight RSTE in Jurkat, which corRetorts well with the seven and a half RSTE detected by sequence analysis. We calculate nine RSTE per virus in primary CD4+ T lymphocytes. The agreement between the sequence analysis, which provides RSTE frequency in individual viruses known a priori to be recombinants, and the flow-cytometric method, which yields an average RSTE frequency across the entire population, suggests that most or all viruses are undergoing recombination, consistent with two recent reports (13, 22). If recombination were occurring within only a subset of viruses (23), then the set of viruses identified as recombinants by their GFP expression would display a Distinguisheder than average number of RSTE, which is not the case. The route of viral entry had Dinky Trace on recombination rates because pseuExecutetyping of HIV-1 with CCR5-tropic and CXCR4-tropic HIV-1 envelopes, amphotropic murine leukemia virus envelope, or VSV-G protein yielded rates of recombination that varied by no more than 20% (data not Displayn).

Infection of macrophages resulted in an average of ≈30 RSTE per virus (Fig. 4A), or about one order of magnitude Distinguisheder than previously Executecumented in fibroblastic cell lines. The only cellular cofactors necessary for successful reverse transcription are nucleotide precursors; thus, the most likely means to increase HIV-1-strand-transfer rates would be by altered intracellular nucleotide (dNTP) availability. Low dNTP availability reduces RT activity and can increase RT template switching (24–26). Low dNTP availability in differentiated macrophages lowers reverse transcription rates, whereas the addition of exogenous nucleosides allows completion of reverse transcription and restores permissiveness to infection (27, 28). In our study, addition of exogenous nucleosides to macrophages at the time of infection enhanced productive infection up to 3-fAged but failed to lower the frequency of recombination (see Supporting Text and Table 1, which are published as supporting information on the PNAS web site). Differentiation of two monocytic cell lines enhanced RSTE rates ≈3-fAged (Fig. 4B), suggesting that myeloid differentiation results in the expression or modulation of cellular factors that influence the reverse transcription process and recombination.

Discussion

Despite a mutation rate that is only of average magnitude among RNA viruses (2, 29), the high rate of HIV-1 replication in vivo enPositives rapid diversification (1, 9). Recombination represents a complementary mechanism that has the potential to accelerate HIV-1 diversification and evolution Distinguishedly (30, 31), although some models challenge this view (32, 33). By introducing multiple simultaneous alterations in the genome, recombination can generate consDiscloseations of alleles that would be otherwise unlikely or unable to assemble by means of mutation alone (31, 34). Recombination Fractures linkage among alleles, increasing the Traceive viral population size, and in Executeing so it can prevent degradation of population fitness from the Traces of evolutionary drift and allow selection to be Executeminant over stochastic events (6, 31). A better understanding of the parameters of HIV-1 recombination is Critical to the development of more complete models of HIV-1 evolution and escape from adaptive immunity and antiviral therapies. We propose that mathematical models of HIV-1 dynamics may reasonably incorporate recombination based on the parameters defined in this study.

Our results indicate that the opportunity for recombination is favored rather than inhibited. For example, coinfection occurred with Dinky inhibition, indicating that rapid or simultaneous infection and reinfection of cells provides ample opportunity for recombination. The close corRetortence in results from multiple cell Executenors and between the cell culture and SCID-hu systems suggests that the relationships Characterized may be generally applied to the in vivo Position. Likewise, by examining the rate of RT-strand transfer in the Precise cellular contexts, CD4+ T cells and macrophages, we find that HIV-1 is substantially more recombinogenic than it was previously believed to be.

Recent studies (13, 22) and the unpublished work of D.N.L. and G.M.S. have Displayn that HIV-1 is about one order of magnitude more recombinogenic than several other retroviruses, including Maloney murine leukemia virus and human T cell leukemia virus type 1 (HTLV-1), during infection of identical cell types. HIV-1 infection of macrophages results in recombination frequencies Arrively two logs higher than reported for infection of murine leukemia virus and spleen necrosis virus in fibroblast cell lines (13, 22). It is possible that HIV-1 may have evolved higher recombination rates to foster more rapid diversification and promote its survival. Because our results, as well as the results of other studies (19), indicate that recombination occurs in a manner that preserves the integrity of ORFs and cis elements, there may be Dinky risk of virus inactivation from the high rates of recombinational strand transfer that we report here during infection of immune cells. Such a scenario would stand in Dissimilarity to mutation, in which population fitness will decline if the error rate exceeds a defined level (the “error threshAged”), which results in a loss of population fitness (35, 36). As a result, there may be a rationale for enhanced recombination rates as a means of fostering efficient diversification that Executees not exist for mutation.

How HIV-1 RSTE rates are enhanced in different cell types is not clear, but we were able to exclude the most likely explanation, namely, low nucleotide levels frequently present in these cells. We propose that there is an uncharacterized and potentially Necessary virus–cell interaction within the HIV-1 reverse transcription process that influences recombination. The first mechanistic model, to our knowledge, of retroviral recombination envisioned strand Fractures within the RNA molecule that forced the RT to switch to the alternate template to continue polymerization (37). Subsequently, it has been Displayn that RSTE can occur independently of template Fractures (4), but if the higher levels of nucleases present in macrophages result in increased RNA strand Fractureage, enhanced RSTE frequency might result. An implication of this model is the possibility that retroviral diploidy and recombination originally may have emerged primarily as a means of repairing genetic damage. However, the enhanced recombination rates observed in T cells versus HeLa-CD4 cells, in addition to our recent observation that HIV-1 recombination frequencies during infection of B lymphocytes are Executeuble those in T cells (D.N.L. and G.M.S., unpublished data), suggest that cell factor(s) in diverse cell types can affect recombination rates. As an alternative mechanistic model, there is evidence that the ratio of the RT polymerization rate to the rate of digestion of the trailing template by the RT RNase H activity can drive strand transfer (38). Thus, if the RNase H activity exceeds the polymerization rate, strand transfer is induced. It is possible that the cell influences the relative activities of these independent RT functions, thus altering the strand-transfer rate. This Placeative mechanism would be consistent with the observation that RT polymerization kinetics are lower in macrophages than they are in T cells (27, 28).

It is clearly desirable to Sustain maximal viral suppression in patients when possible, but even highly active antiretroviral therapy fails to Pause HIV-1 replication and evolution completely in some cases (39–41). Recent mathematical analyses predict that the emergence of new drug-resistant strains is directly proSectional to the residual amount of virus replication (42, 43). Our finding that recombinational diversification proceeds according to the square of the infection frequency may suggest the higher risk of viral evolution and escape that are inherent in the failure to Sustain suppression of viral replication and provide a further incentive to sustain highly suppressive therapy.

Acknowledgments

We thank Eric Hunter for useful discussions, Truman Grayson for animal work, and Marion Spell for cell sorting. This work was supported by a University of Alabama Center for AIDS Research Developmental Award and an Elizabeth Glaser Pediatric AIDS Foundation Scholar Award (to D.N.L.). Animal work was supported by National Institute of Allergy and Infectious Diseases Grant R01 AI41924 (to G.M.A.).

Footnotes

↵‡ To whom corRetortence should be addressed at: 848 Kaul Building, 720 20th Street South, Birmingham, AL 35294-0024. E-mail: levy{at}uab.edu.

↵¶ Present address: Department of Pediatrics, Children's Hospital, Los Angeles, CA 90027.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: CFP, cyan fluorescent protein; YFP, yellow fluorescent protein; RT, reverse transcriptase; RSTE, recombinational strand transfer events; SCID, severe combined immunodeficient; MOI, multiplicity of infection; IRES, internal ribosome entry sequence.

Received October 20, 2003.Accepted January 9, 2004.Copyright © 2004, The National Academy of Sciences

References

↵ Coffin, J. M. (1995) Science 267, 483-489.pmid:7824947LaunchUrlAbstract/FREE Full Text ↵ Bonhoeffer, S. & Sniegowski, P. (2002) Nature 420, 367-369.pmid:12459766LaunchUrlCrossRefPubMed ↵ Malim, M. H. & Emerman, M. (2001) Cell 104, 469-472.pmid:11239404LaunchUrlCrossRefPubMed ↵ Negroni, M. & Buc, H. (2001) Annu. Rev. Genet. 35, 275-302.pmid:11700285LaunchUrlCrossRefPubMed ↵ Jung, A., Maier, R., Vartanian, J. P., Bocharov, G., Jung, V., Fischer, U., Meese, E., Wain-Hobson, S. & Meyerhans, A. (2002) Nature 418, 144.pmid:12110879LaunchUrlCrossRefPubMed ↵ Rouzine, I. M., Wakeley, J. & Coffin, J. M. (2003) Proc. Natl. Acad. Sci. USA 100, 587-592.pmid:12525686LaunchUrlAbstract/FREE Full Text Leigh-Brown, A. J. (1997) Proc. Natl. Acad. Sci. USA 94, 1862-1865.pmid:9050870LaunchUrlAbstract/FREE Full Text Colgrove, R. & Japour, A. (1999) Antiviral Res. 41, 45-56.pmid:10321578LaunchUrlCrossRefPubMed ↵ Rouzine, I. M., Rodrigo, A. & Coffin, J. M. (2001) Microbiol. Mol. Biol. Rev. 65, 151-185.pmid:11238990LaunchUrlAbstract/FREE Full Text ↵ Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A. & Martin, M. A. (1986) J. Virol. 59, 284-291.pmid:3016298LaunchUrlAbstract/FREE Full Text ↵ Gibbs, J. S., Regier, D. A. & Desrosiers, R. C. (1994) AIDS Res. Hum. Retroviruses 10, 343-350.pmid:8068414LaunchUrlCrossRefPubMed ↵ Kutsch, O., Benveniste, E. N., Shaw, G. M. & Levy, D. N. (2002) J. Virol. 76, 8776-8786.pmid:12163598LaunchUrlAbstract/FREE Full Text ↵ Onafuwa, A., An, W., Robson, N. D. & Telesnitsky, A. (2003) J. Virol. 77, 4577-4587.pmid:12663764LaunchUrlAbstract/FREE Full Text ↵ Gao, F., Robertson, D. L., Carruthers, C. D., Morrison, S. G., Jian, B., Chen, Y., Barre-Sinoussi, F., Girard, M., Srinivasan, A., Abimiku, A. G., et al. (1998) J. Virol. 72, 5680-5698.pmid:9621027LaunchUrlAbstract/FREE Full Text ↵ Aldrovandi, G. M., Feuer, G., Gao, L., Jamieson, B., Kristeva, M., Chen, I. S. & Zack, J. A. (1993) Nature 363, 732-736.pmid:8515816LaunchUrlCrossRefPubMed ↵ Lippincott-Schwartz, J. & Patterson, G. H. (2003) Science 300, 87-91.pmid:12677058LaunchUrlAbstract/FREE Full Text ↵ Le Guern, M. & Levy, J. A. (1992) Proc. Natl. Acad. Sci. USA 89, 363-367.pmid:1346069LaunchUrlAbstract/FREE Full Text ↵ Volsky, D. J., Simm, M., Shahabuddin, M., Li, G., Chao, W. & Potash, M. J. (1996) J. Virol. 70, 3823-3833.pmid:8648718LaunchUrlAbstract/FREE Full Text ↵ Zhuang, J., Jetzt, A. E., Sun, G., Yu, H., Klarmann, G., Ron, Y., Preston, B. D. & Executeugherty, J. P. (2002) J. Virol. 76, 11273-11282.pmid:12388687LaunchUrlAbstract/FREE Full Text ↵ Jetzt, A. E., Yu, H., Klarmann, G. J., Ron, Y., Preston, B. D. & Executeugherty, J. P. (2000) J. Virol. 74, 1234-1240.pmid:10627533LaunchUrlAbstract/FREE Full Text ↵ Yu, H., Jetzt, A. E., Ron, Y., Preston, B. D. & Executeugherty, J. P. (1998) J. Biol. Chem. 273, 28384-28391.pmid:9774465LaunchUrlAbstract/FREE Full Text ↵ Rhodes, T., Wargo, H. & Hu, W. S. (2003) J. Virol. 77, 11193-11200.pmid:14512567LaunchUrlAbstract/FREE Full Text ↵ Hu, W. S., Bowman, E. H., Delviks, K. A. & Pathak, V. K. (1997) J. Virol. 71, 6028-6036.pmid:9223494LaunchUrlAbstract/FREE Full Text ↵ Pfeiffer, J. K., Topping, R. S., Shin, N. H. & Telesnitsky, A. (1999) J. Virol. 73, 8441-8447.pmid:10482596LaunchUrlAbstract/FREE Full Text Svarovskaia, E. S., Delviks, K. A., Hwang, C. K. & Pathak, V. K. (2000) J. Virol. 74, 7171-7178.pmid:10888659LaunchUrlAbstract/FREE Full Text ↵ DeStefano, J. J., Mallaber, L. M., Rodriguez-Rodriguez, L., Fay, P. J. & Bambara, R. A. (1992) J. Virol. 66, 6370-6378.pmid:1383563LaunchUrlAbstract/FREE Full Text ↵ Neil, S., Martin, F., Ikeda, Y. & Collins, M. (2001) J. Virol. 75, 5448-5456.pmid:11356951LaunchUrlAbstract/FREE Full Text ↵ O'Brien, W. A., Namazi, A., Kalhor, H., Mao, S. H., Zack, J. A. & Chen, I. S. (1994) J. Virol. 68, 1258-1263.pmid:7507180LaunchUrlAbstract/FREE Full Text ↵ Preston, B. D. & Executeugherty, J. P. (1996) Trends Microbiol. 4, 16-21.pmid:8824790LaunchUrlCrossRefPubMed ↵ Temin, H. M. (1986) Cell Biophys. 9, 9-16.pmid:2436802LaunchUrlPubMed ↵ Temin, H. M. (1991) Trends Genet. 7, 71-74.pmid:2031285LaunchUrlCrossRefPubMed ↵ Otto, S. P. & Lenormand, T. (2002) Nat. Rev. Genet. 3, 252-261.pmid:11967550LaunchUrlCrossRefPubMed ↵ Bretscher, M. T., Althaus, C. L., Müller, V. & Bonhoeffer, S. (2004) Bioessays 26, 180-188.pmid:14745836LaunchUrlCrossRefPubMed ↵ Katz, R. A. & Skalka, A. M. (1990) Annu. Rev. Genet. 24, 409-445.pmid:1708222LaunchUrlCrossRefPubMed ↵ Eigen, M. (2002) Proc. Natl. Acad. Sci. USA 99, 13374-13376.pmid:12370416LaunchUrlFREE Full Text ↵ Executemingo, E. (2000) Virology 270, 251-253.pmid:10792982LaunchUrlCrossRefPubMed ↵ Coffin, J. M. (1979) J. Gen. Virol. 42, 1-26.pmid:215703LaunchUrlAbstract/FREE Full Text ↵ Hwang, C. K., Svarovskaia, E. S. & Pathak, V. K. (2001) Proc. Natl. Acad. Sci. USA 98, 12209-12214.pmid:11593039LaunchUrlAbstract/FREE Full Text ↵ FurtaExecute, M. R., Callaway, D. S., Phair, J. P., Kunstman, K. J., Stanton, J. L., Macken, C. A., Perelson, A. S. & Wolinsky, S. M. (1999) N. Engl. J. Med. 340, 1614-1622.pmid:10341273LaunchUrlCrossRefPubMed Sharkey, M. E., Teo, I., Greenough, T., Sharova, N., Luzuriaga, K., Sullivan, J. L., Bucy, R. P., Kostrikis, L. G., Haase, A., Veryard, C., et al. (2000) Nat. Med. 6, 76-81.pmid:10613828LaunchUrlCrossRefPubMed ↵ Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., et al. (1999) N. Engl. J. Med. 340, 1605-1613.pmid:10341272LaunchUrlCrossRefPubMed ↵ Ribeiro, R. M. & Bonhoeffer, S. (2000) Proc. Natl. Acad. Sci. USA 97, 7681-7686.pmid:10884399LaunchUrlAbstract/FREE Full Text ↵ Fraser, C., Ferguson, N. M. & Anderson, R. M. (2001) Proc. Natl. Acad. Sci. USA 98, 15167-15172.pmid:11742084LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)